Tim Van Hauwermeiren and Samantha Du
EXCLUSIVE: Zai Lab’s Samantha Du scoops up China rights to an autoimmune drug with a hefty $175M licensing deal — heavily fronted with cash and stock
Argenx $ARGX has just scored a major licensing pact with Samantha Du’s Zai Lab, and it includes some of the largest numbers in cash and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
